Brian Horn, DO
Family Medicine · Dover, DENPI 1518922574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 162 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$423
- Novo Nordisk$419
- AstraZeneca$350
- Merck$293
- Pfizer$223
- Dexcom, Inc.$185
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,010100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 22 | $423 |
| Novo Nordisk | 34 | $419 |
| AstraZeneca | 15 | $350 |
| Merck | 15 | $293 |
| Pfizer | 13 | $223 |
| Dexcom, Inc. | 4 | $185 |
| Sanofi Pasteur Inc. | 8 | $150 |
| Astellas Pharma US Inc | 7 | $125 |
| GSK | 5 | $90 |
| Abbott | 4 | $83 |
| Shield Therapeutics Inc | 3 | $81 |
| Exact Sciences | 4 | $79 |
| Supernus Pharmaceuticals, Inc. | 2 | $57 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Scilex Pharmaceuticals Inc. | 2 | $44 |
| Amarin Pharma, Inc. | 3 | $43 |
| Amgen | 2 | $42 |
| Shire North American Group Inc | 3 | $38 |
| Averitas Pharma Inc. | 1 | $34 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Medtronic | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$125
- AIRSUPRA$117
How this compares
$3,010 in reported general payments places this provider in the 80th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 91 | $124,347 |
| JanuviaSitagliptin Phosphate | 42 | $61,845 |
| EliquisApixaban | 36 | $34,479 |
| OzempicSemaglutide | 16 | $19,490 |
| TradjentaLinagliptin | 22 | $16,989 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $16,154 |
| RybelsusSemaglutide | 14 | $14,408 |
| OxycontinOxycodone Hcl | 14 | $13,667 |
| XareltoRivaroxaban | 18 | $10,076 |
| Rosuvastatin Calcium | 201 | $4,068 |
| Omeprazole | 259 | $3,895 |
| Atorvastatin Calcium | 343 | $3,795 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $3,678 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,295 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $3,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $21 | $141,335113 claims |
| MerckJanuvia | $293 | $61,84542 claims |
| PfizerEliquis, Paxlovid | $223 | $35,90858 claims |
| Novo NordiskOzempic, Rybelsus | $419 | $33,89830 claims |
| GSKTrelegy Ellipta | $90 | $16,15413 claims |
| Johnson & JohnsonXarelto | $12 | $10,07618 claims |
| Lilly USA, LLCHumulin 70-30 | $423 | $1,74612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 352 family medicine providers in Delaware.
Other family medicine in Dover
- Nadiene HaynesDover$10K
- Thuya AyeDover$8K
- Lawrence LewandowskiDover$7K
- Kenny VuDover$3K
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.